17,261 trials
Aggressive Systemic Mastocytosis · Mast Cell Leukemia · Systemic Mastocytosis
Primary: Overall Response Rate (ORR) Per Consensus International Response Criteria (Rate of Complete or Partial Remissions or Clinical Improvement) — 0 participants
Nonalcoholic Steatohepatitis (NASH)
Primary: Overall Safety of GS-9674 as Assessed By Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 89.3; 76.8; 67.9; 1.8 Percentage of…
Prostate Cancer
Primary: Number of Patients Who Achieve a PSA ≤ 4ng/mL After Seven Months of Protocol Treatment in Each Arm — 16; 32 Participants — p=0.87
Influenza
Primary: Number of Participants With Seroconversion to A/California/07/2009 (H1N1) — 41; 21 Participants
Toothache
Primary: Mean of Pain Intensity Based on the Visual Analogue Scale (VAS) — 37.45; 34.95; 38.84; 17.15 Scores on a Scale
Asthma
Primary: Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12 — 5.80; -6.04 cells/mm^2 — p=0.8400
Schizophrenia · Schizoaffective Disorder · Schizophreniform Disorder
Primary: Change in Weight — -2.0021; -1.5490 kg. (killograms)
Advanced and Metastatic Silent Neuro-Endocrine Tumors · Carcinoma · Neuroendocrine
Primary: Percentage of Participants' Best Overall Response Rate at 12 Months - Per Protocol Set (PP) — 0.0; 0.0; 56.7; 43.3 percentage of participants
Acute Lymphoblastic Leukemia
Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants
Metastatic Seminoma
Primary: 2 - Year Progression Free Survival — 46 Participants
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or · Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
Primary: Number of Participants Contributing to the Overall Response Rate — 34 participants
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Endometrial Serous Adenocarcinoma
Primary: Progression Free Survival Rate — 0.52; 0.40; 0.71; 0.84 proportion of patients
Musculoskeletal Pain
Primary: Subject's Assessment of Pain Using the Numeric Pain Rating Scale (AUC16h-96h) — 289.18; 341.78; 401.75; 290.55 units on a Scale*hours
Premature Ejaculation
Primary: Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT) — 2.1; 1.1 No units for fold change